Meet with... National Cancer Institute

Add this event to your calendar:
08/08/2016 14:15 08/08/2016 17:00 America/Los_Angeles Meet with... National Cancer Institute [email protected] , 953 Indiana Street , San Francisco , CA 94107 JLABS Bay Area false DD/MM/YYYY
August
8
Event

Meet with... National Cancer Institute

[email protected] , 953 Indiana Street , San Francisco , CA 94107

August 08, 2016 from 14:15 PM to 17:00 PM (PST)

$10 - $35


The National Cancer Institute Small Business Innovation Research (NCI SBIR) Development Center is coming to [email protected]! Director Michael Weingarten and program manager Christie Canaria will be presenting funding opportunities and other resources for startups in cancer technology. You will also learn about 15 new targeted funding opportunities in cancer detection, diagnosis and treatment in high priority areas of research for the NCI. Although the trends reflect improvements in cancer treatments and advances in technology have led to better tools for understanding, detecting and diagnosing cancer, we still have work to do. In 2016, an estimated 1,685,210 new cases of cancer will be diagnosed in the United States. The NCI is poised to reduce the burden of cancer in this country and around the world at an accelerated pace.

Program Overview:
NCI PRESENTS CURRENT AND NEW FUNDING OPPORTUNITIES
Director Michael Weingarten and Program Manager Christie Canaria will discuss the exciting new non-dilutive targeted funding opportunities in cancer focused technology development. They will explain the application and review process at the NIH to help small businesses submit stronger applications. Additionally, the presentation will review the I-Corps at NIH program, other initiatives run by NCI to facilitate the success of SBIR companies, and the latest news regarding the Vice President's cancer initiative, the Cancer Moonshot.

Following the presentation, selected companies will have the opportunity to meet one-on-one with NCI. To be considered for a one-on-one meeting, please contact Christie Canaria, by July 29th with your name, company name, and a short executive summary of your company as well as the technology project you would like to discuss with the NCI.

This is event is being held in cooperation with QB3 @ 953


Agenda:
12:15 PM | Registration Opens
12:45 PM | Networking Lunch
1:30 PM | Presentation and Q&A
3:00 PM | Program Close
3:15-5:30 PM | One-on-one Meetings*

*Companies must have applied for a one-on-one meeting ahead of time and be approved. To be considered for a one-on-one meeting, please contact Christie Canaria, by July 29th with your name, company name, and a short executive summary of your company as well as the technology project you would like to discuss with the NCI.


National Cancer Institute Participating Representatives:
Michael Weingarten | Director, SBIR Development Center, National Cancer Institute read bio»
Christie Canaria |Program Manager, SBIR Development Center, National Cancer Institute read bio»


About the National Cancer Institute:
The National Cancer Institute (NCI) is part of the National Institutes of Health (NIH), which is one of 11 agencies that compose the Department of Health and Human Services (HHS). The NCI, established under the National Cancer Institute Act of 1937, is the Federal Government's principal agency for cancer research and training. The National Cancer Act of 1971 broadened the scope and responsibilities of the NCI and created the National Cancer Program. Over the years, legislative amendments have maintained the NCI authorities and responsibilities and added new information dissemination mandates as well as a requirement to assess the incorporation of state-of-the-art cancer treatments into clinical practice. The National Cancer Institute coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients.
Connect with the NCI:   Connect on LinkedIn   Follow on Twitter


Fees:
Presentation & Lunch
$25 | General Public
$35 | General Public Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Registration to attend the presentation, Q&A, and lunch will remain open until Aug 7th (or sold out).

One-on-One Meeting
FREE | Application
FREE | Accepted Companies
Companies must have applied for a one-on-one meeting ahead of time and be approved. To be considered for a one-on-one meeting, please contact Christie Canaria, by July 29th with your name, company name, and a short executive summary of your company as well as the technology project you would like to discuss with the NCI.


About the Meet with... Series:
The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCI, NCATS, NINDS, Allegory Venture Partners, Clarus Ventures, Johnson & Johnson Innovation, Poliwogg, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.


Venue:
[email protected]
953 Indiana Street
San Francisco, California


National Cancer Institute Participating Representatives' Biographies:
Michael Weingarten | Director, SBIR Development Center, National Cancer Institute
Michael Weingarten is the Director for the Small Business Innovation Research (SBIR) Development Center at the National Cancer Institute in Bethesda, MD. In this role, Mr. Weingarten leads a team of nine Program Directors who manage all aspects of the NCI SBIR & STTR Programs including a portfolio of $135M in grants and contracts annually. The SBIR & STTR programs are NCI's engine of innovation for developing and commercializing novel technologies and products to prevent, diagnose, and treat cancer. Mr. Weingarten has implemented a set of key initiatives for optimizing the performance of the NCI SBIR Program at the NIH. These include the establishment of a new model at the NCI for managing the program - the SBIR Development Center.
Under Mr. Weingarten's leadership, the NCI SBIR Development Center has launched a range of new initiatives to facilitate the success of small businesses developing cancer-related technologies. Recent initiatives include the launch of the NIH I-Corps™ pilot program in which teams of budding entrepreneurs engage in a hypothesis-driven approach to validate their proposed business models by conducting over 100 interviews with potential customers. Companies adjust their strategies based on direct customer feedback and analyze the information they collect to determine if there is a product/market fit. Other NCI SBIR initiatives introduced under Mr. Weingarten's leadership include the NCI SBIR Investor Forums, the NCI SBIR Phase II Bridge Award, and the workshop titled Federal Resources to Accelerate Commercialization (FRAC). Thus far, NCI SBIR has held three investor forums that in total have facilitated the closing of investment deals with NCI-funded SBIR companies valued at over $300M. The NCI SBIR Phase II Bridge Award, which was launched in 2009, incentivizes partnerships between NIH's SBIR Phase II awardees and third-party investors and/or strategic partners to help small businesses bridge the funding gap between the end of their SBIR Phase II awards and the next round of financing needed to advance a promising cancer therapy or imaging technology.



Christie Canaria, Ph.D. | Program Manager, SBIR Development Center, National Cancer Institute
Dr. Christie Canaria is a Program Manager in the Small Business Innovation Research (SBIR) Development Center at the National Cancer Institute (NCI). She provides programmatic support to small businesses applying to the SBIR and STTR programs and has areas of expertise in biological imaging, biosensors, and nanotechnology. Dr. Canaria is a central figure in planning special center initiatives, conducting outreach activities, and coordinating communications. In 2014, she played a leading role in launching the Innovation Corps (I-Corps™) at NIH Pilot, a program designed to support training to help project teams at NIH-funded small businesses overcome key obstacles along the path of innovation and commercialization.
In 2013, Dr. Canaria was awarded the AAAS Science & Technology Policy Fellowship and began science policy work in Washington, DC. Previously, she managed an optical microscopy facility at DOE Lawrence Berkeley National Laboratory as an imaging expert and neurobiologist; she was also a coordinator and imaging expert at the Caltech Biological Imaging Center where she developed advanced, multi-dimensional and time-lapse confocal imaging techniques. Dr. Canaria also worked in industry, expanding and optimizing surface chemistry and imaging processes for genome sequencing technologies. Dr. Canaria earned her Ph.D. in Chemistry from the California Institute of Technology and a B.S. in Chemistry from the University of California, San Diego.



JLABS Bay Area

About Johnson & Johnson Innovation, JLABS Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow. At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries. JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property. JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and healthtech sectors. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then has grown to ten global locations including the Bay Area, Boston & Lowell, MA, Houston, Toronto, Beerse (Belgium), with New York City, opening in June 2018, and Shanghai in 2019. For more information please visit www.jlabs.jnjinnovation.com or follow @JLABS. About Johnson & Johnson Innovation Johnson & Johnson Innovation LLC focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson's global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers, Johnson & Johnson Innovation | JLABS, Johnson & Johnson Innovation - JJDC, Inc. and our Business Development teams to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in patients. For more information please visit www.jnjinnovation.com or follow @JNJInnovation.

Event contact


Related content